The optimal blood pressure (BP) target remains debated in nondiabetic patients with chronic kidney disease (CKD).
C hronic kidney disease (CKD) is a global epidemic, and it leads to higher risks of dialysis, cardiovascular morbidity, and mortality. [1] [2] [3] The prevalence of CKD varies from 8% to 16% worldwide, with nondiabetic CKD accounts for most of the CKD population. [4] [5] [6] [7] The development and progression of nondiabetic CKD are closely interrelated to hypertension, and blood pressure (BP) control is able to decrease the risk of decline in renal function and cardiovascular mortality. [7] [8] [9] [10] [11] However, the optimal BP target for preventing kidney disease progression remain debated. Major guidelines suggest a target of BP of less than 140/90 mm Hg for patients with nondiabetic CKD, 12, 13 and some suggest a further reduction to achieve a BP of less than 130/80 mm Hg for those with proteinuria. 8, 14 Previous randomized clinical trials (RCTs) and systematic reviews have examined the renoprotective effects of an intensive BP control in patients with nondiabetic CKD but reported conflicting results. [15] [16] [17] [18] [19] [20] Recently, the Systolic Blood Pressure Intervention Trial (SPRINT) reported that intensive BP control did not significantly reduce the risk of dialysis or declined renal function in nondiabetic patients with CKD, but rather increased the risk of acute kidney injury. 21 In this systematic review and meta-analysis, we synthesized results from RCTs to evaluate the effects of intensive BP-lowering treatment on major renal outcomes and mortality in nondiabetic adults with CKD, and also assessed effect modification by proteinuria.
Methods

Data Sources and Literature Searches
We conducted electronic literature searches of PubMed, MEDLINE, Embase, and the Cochrane Library from the earliest available date of indexing through March 24, 2016. We also hand-searched the reference lists of identified publications for additional studies. The detailed study protocol and search strategies are provided in the eAppendix 1 in the Supplement.
Study Selection
We included RCTs comparing different BP targets in primarily nondiabetic CKD patients older than 18 years. Included studies had to report at least 1 of the outcomes: changes in glomerular filtration rate (GFR), doubling of serum creatinine level, 50% reduction in GFR, end-stage renal disease (ESRD), or all-cause mortality. Studies reporting outcomes from nondiabetic CKD subgroups were included. Eligible studies had to be published as full-length articles in peer-reviewed journals.
Data Extraction and Quality Assessment
Two investigators (W.-C.T. and H.-Y.W. ) independently extracted relevant information from the included studies and evaluated the methodological quality of eligible trials by using the Cochrane Collaboration's tool for assessing risk of bias.
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Disagreements between the 2 investigators were resolved by discussion.
Outcomes
Comparing the intensive BP-lowering treatment with the standard BP-lowering treatment during the in-trial follow-up period, our outcomes of interest were the annual rate of change in GFR, doubling of serum creatinine level, or 50% reduction in GFR, ESRD, and all-cause mortality. We also analyzed the composite renal outcome of the doubling of serum creatinine level, 50% reduction in GFR, or ESRD. ESRD was defined as the need for dialysis therapy or kidney transplantation.
Data Synthesis and Analysis
Categorical variables are presented as frequencies or percentages, and continuous variables are presented as mean values unless stated otherwise. The pooled estimates of effect measures and 95% CIs of comparisons between the intensive and standard BP-lowering treatments were calculated using both the fixed-effect model and the DerSimonian and Laird randomeffects model. 22 The effect size of continuous outcome (annual rate of change in GFR; milliliters per minutes per 1.73 m 2 per year) was expressed as mean difference with 95% CI. We used estimation and imputation methods to reconstruct the missing values for annual rate of change in GFR as recommended in the Cochrane Handbook (eAppendix 2 in the Supplement). 22 Effect sizes of binary outcomes (doubling of serum creatinine level or 50% reduction in GFR, ESRD, composite renal outcome, and all-cause mortality) were expressed as risk ratios (RRs) with 95% CIs. In consideration of between-study variance, we used the random-effects model as the primary analyses.
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Publication bias was examined using the funnel plot method and Egger regression asymmetry test.
24,25 Heterogeneity of treatment effects across studies were assessed by I 2 and the Cochrane Q-test. 22 Meta-regression and subgroup analyses were performed to explore potential sources of heterogeneity and assess the associations between variables and intervention effects. We conducted meta-regression using mixed-effects model to assess the influences of mean age, race, mean baseline GFR, targeted systolic BP, study sample size, or the method of GFR measurement. Subgroup analysis was performed when a covariate was significant in the metaregression. Owing to the wide range, the level of proteinuria was not suitable to be assessed as a study-level covariate in meta-regression or subgroup analyses. To determine whether the level of proteinuria influenced the effects of intensive BPlowering treatment, we extracted available subpopulation data from each study and pooled their results for ESRD or annual
Key Points
Question Does intensive blood pressure control provide better renoprotection for nondiabetic chronic kidney disease?
Findings In this systematic review including 9 randomized clinical trials with 8127 patients and a median follow-up of 3.3 years, intensive and standard blood pressure control provided similar effects. However, nonblack patients and those with higher levels of proteinuria showed a trend of lower risk of kidney disease progression with intensive blood pressure-lowering treatments.
Meaning Targeting blood pressure below the current standard is not consistently warranted, but may benefit nonblack patients or those with heavy proteinuria.
rate of change in GFR. To assess the robustness of our metaanalyses, we undertook sensitivity analyses by omitting studies with imputed missing data, or studies that did not totally exclude diabetic patients. To compare with previous metaanalysis, 19 we also carried out a sensitivity analysis by includ- 
Results
The flowchart in eFigure 1 in the Supplement shows the literature search process. Of the 1158 articles retrieved initially, 328 were excluded due to duplicate publication and 816 were excluded on the basis of titles and abstracts. Of the 14 that underwent full-text evaluation, 10 articles met the inclusion criteria.
Study Characteristics and Quality Assessment
There were 9 RCTs from 10 eligible articles, which enrolled a total of 8127 participants. The clinical and methodological characteristics of each study are summarized in Table 1 and  Table 2 . The median length of in-trial follow-up was 3.3 years (range, 1.6-7.0 years (Figure, D) , or all-cause mortality (RR, 0.95; 95% CI, 0.66-1.37) (Figure, E) . The funnel plots and the Egger regression asymmetry test indicated no significant publication bias for any outcome (eFigure 4 in the Supplement). There was no statistical heterogeneity for any outcomes (I 2 = 0%; P > .05) (Figure) .
Results were similar after omitting studies with imputed missing data for the annual rate of change in GFR (mean difference, 0.09; 95% CI, −0.38 to 0.55 mL/min/1.73 m 2 /y) (eFigure 5 in the Supplement). Results were also similar in sensitivity analyses omitting results of the JATOS and MDRD studies, which enrolled a small percentage of diabetic patients (eTable1intheSupplement). Sensitivity analysis, including the posttrial follow-up data of the MDRD and the AASK studies, Table 3 lists the results of univariable meta-regression analyses for exploring potential sources of between-study heterogeneity. Meta-regression showed that the annual rate of decline in GFR with intensive BP control tended to be faster among blacks compared with nonblacks (β value, −0.44; 95% CI, −0.96 to 0.07 mL/min/1.73 m 2 /y; P = .09) (Table 3) . Subgroup analyses (eFigure 7 in the Supplement) showed a trend of faster decline in GFR for intensive BP control among studies including mostly blacks (mean difference, −0.26; 95% CI, −0.70 to 0.18 mL/min/1.73 m 2 /y), and a slower decline in GFR among studies with nonblacks (mean difference, 0.18; 95% CI, −0.08 to 0.45; P for interaction = .09).
Meta-regression and Subgroup Analyses
Influence of the Level of Proteinuria on Effects of Intensive BP-Lowering Treatments
Only the annual rate of change in GFR and ESRD could be assessed by different levels of proteinuria. Overall, the effects of intensive BP control were not significantly different among patients with different levels of proteinuria (eTables 2 and 3 in the Supplement). However, there was a trend for intensive BP control to slow the rate of decline in GFR level among patients with proteinuria higher than 1 g/d (mean difference, 0.75; 95% CI, −0.40 to 1.89 mL/min/1.73 m 2 /y; P for interaction = .15), and a trend of lower risk for ESRD among those with proteinuria level higher than 0.5 g/d (RR, 0.92; 95% CI, 0.70-1.21; P for interaction = .43). 
Adverse Events of Intensive BP Control
Discussion
In this systematic review and meta-analysis of nondiabetic adults with CKD, there were no differences in renal outcomes comparing intensive and standard BP-lowering strategies during a median follow-up of 3.3 years. However, nonblacks and patients with higher levels of proteinuria showed a trend of lower risk of kidney disease progression with intensive BPlowering treatments. There was no clear evidence that intensive BP control increased the risk of adverse events, except for the symptom of dizziness. These estimates are fairly robust and changed little in sensitivity analyses. 
Strengths of This Study
This systematic review provides up-to-date information and included more than 8000 patients and more than 800 events of kidney disease progression. Five study outcomes were analyzed to evaluate effects of intensive BP-lowering treatments, and all showed similar results. We followed a standard protocol, used a comprehensive search strategy, and applied rigorous methods to assess the robustness of study results, including meta-regression and subgroup analyses.
Results in Relation to Other Studies and Reviews
Our study results are consistent with those of previous metaanalyses. might not clarify the effects of intensive BP control. To maintain the pooled evidence in the highest quality, we included only data from nondiabetic adults during the trial phase, and showed that the intensive and standard BP control provided similar effects during a follow-up of 3.3 years. We also noted a trend of better renal outcomes for intensive BP control among patients with higher levels of proteinuria, but this finding did not reach statistical significance during this timeframe of follow-up. Compared with whites, blacks with hypertension are more prone to develop CKD and progress to ESRD, and this is likely to involve a complex interaction between biological and socioeconomic factors. [37] [38] [39] Previous studies have reported that the kidney protection with antihypertensive therapy is less favorable in blacks than in whites. 18,40 Similarly, we found a trend that only nonblacks gained additional kidney protection from intensive BP lowering. However, statistical power in our metaanalysis to address effects in blacks is relatively limited because there were only 2 RCTs among the black population.
Limitations
Our study has several limitations. First, there was betweenstudy variability owing to different patient characteristics and trial designs among included studies. The causes of CKD (hypertension, glomerulonephritis, polycystic kidney disease, or other causes) and the types of BP target (systolic BP, diastolic BP, or mean arterial pressure) varied across included studies.
In spite of the efforts in meta-regression and subgroup analyses, we could only partly explain the influences of race or proteinuria on intervention effects. The number of included studies limited power for further exploration with multivariable meta-regression or multilevel subgroup analyses. Second, achieved BP could result in unblinding of the included trials. Nevertheless, the objective nature of the outcome measures reduced the possible impact of the lack of blinding. Third, most of the included studies had a follow-up time shorter than 4 years because we only included data during the trial phase. The length of follow-up might not have been long enough to distinguish outcome differences among the overall study population. Fourth, this systematic review included information from published studies only. Although funnel plots and Egger test did not suggest publication bias, such bias could still exist owing to the relatively low power of these statistical tests. Finally, this study was designed to evaluate nondiabetic patients with CKD and focused on renal outcomes. Further studies are needed to evaluate the cardioprotective effects of intensive BP-lowering treatments in nondiabetic CKD patients.
Conclusions
Targeting BP below the current standard did not provide additional benefit for renal outcomes compared with standard treatment during a follow-up of 3.3 years in patients with CKD without diabetes. However, nonblack patients or those with higher levels of proteinuria might benefit from the intensive BP lowering, and the risk of adverse events are mostly similar among different BP targets. 
Inclusion Criteria
Study type  Randomized, parallel-group design clinical trials but not cross-over or cohort design.  Studies that compared two treatment arms, an intensive blood pressure target versus a standard blood pressure target, to assess kidney disease outcomes.  Studies that used any class of blood pressure lowering drugs.
Participants  Eligible studies should have included nondiabetic adult participants older than 18 years.  Studies with any stage of CKD, except the dialysis population, will be included  Studies reporting outcomes from nondiabetic CKD subgroups will also be included.
Outcome measures  Eligible studies should have reported at least one of the following outcomes: annual rate of change in glomerular filtration rate (GFR) (milliliters per minutes per 1.73 m2 per year), doubling of serum creatinine level, or 50% reduction in GFR, end-stage renal disease (ESRD), or all-cause mortality.  We will also analyze the composite renal outcome of the doubling of serum creatinine level, 50% reduction in GFR, or ESRD.  We will only analyzed outcomes reported during the in-trial follow-up period.  ESRD is defined as the need for dialysis therapy or kidney transplantation.
Publication type  Full-length articles in peer-reviewed journals will be eligible.  Language of publication will not be restricted.
Data extraction and quality assessment
Two investigators (Wan-Chuan Tsai, Hon-Yen Wu) will independently extract the following information: details of study design, location and published year of study, patients' characteristics (age, sex, ethnicity, cause of CKD, level of proteinuria), baseline renal function, baseline blood pressure level, target and achieved level of blood pressure in each treatment arm, classes of blood pressure lowering drugs, follow-up duration, outcome events, and adverse events. The methodological quality of eligible trials will be evaluated independently by two investigators (Wan-Chuan Tsai, Hon-Yen Wu) using "the Cochrane Collaboration's tool for assessing risk of bias" (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias). 1 When relevant information regarding design or outcomes is unclear, or when doubt exists about duplicate publications, the original authors will be contacted for clarifications. Disagreements between the two authors will be resolved by discussion. If the disagreement persists, two other senior investigators (Kuan-Yu Hung, Kuo-Liong Chien) will be consulted to reach a consensus.
Data Synthesis and Analysis
All data from each eligible study will be extracted and entered into a spreadsheet (Excel 2007; Microsoft Corporation, Redmond, WA). Categorical variables will be presented as frequencies or percentages, while continuous variables will be presented as mean values, unless stated otherwise. The effect measures from studies with the same outcome will be pooled by meta-analysis. The pooled estimates of effect measures and 95% confidence intervals (CIs) of comparisons between the intensive and standard blood pressure lowering treatments will be calculated using both the fixed-effect model and the DerSimonian and Laird random-effects model. 1 The effect size of continuous outcome (annual rate of change in GFR; mL/min/1.73 m 2 /y) will be expressed as mean difference (MD) with 95% CI. The annual rate of decline in GFR is significantly slower for the intensive blood pressure lowering treatment if the effect size is significantly greater than zero, and vice versa. Effect sizes of binary outcomes (doubling of serum creatinine level or 50% reduction in GFR, ESRD, composite renal outcome, and all-cause mortality) will be expressed as risk ratios (RRs) with 95% CIs. The intensive blood pressure lowering treatment shows a lower risk if the effect size is significantly less than 1, and vice versa. To make an appropriate choice between the fixed-effect and random-effects models, the recommendations of Borenstein were followed. 2 Publication bias will be examined using the funnel plot method and the Egger's regression asymmetry test. 3, 4 Heterogeneity of treatment effects across studies will be assessed by I-squared (I 2 ) and the Cochrane Q-test. 1 We will perform meta-regression using mixed-effects model to explore potential sources of heterogeneity and assess the associations between variables and intervention effects. Variables potentially associated with renal outcomes will be served as covariates in the meta-regression, including age, race, baseline GFR, targeted blood pressure, sample size, and method of GFR measurement, etc. 5, 6 The magnitude of such relationship will be quantified using R 2 , the proportion of variance explained by the model. Subgroup analysis will be performed if a covariate is significant in the meta-regression. To assess the robustness of the pooled estimates, sensitivity analyses will be undertaken by the same statistical methods after omission of data from specific studies (studies with imputed missing data, studies that did not exclude diabetic subjects). We will also carry out sensitivity analyses by enrolling data of post-trial follow-up periods of the included randomized clinical trials. A two-sided P ≤ 0.05 is considered statistically significant. Statistical analyses will be performed with R software (version 3.2.4, R Foundation for Statistical Computing, Vienna, Austria).
eAppendix 2. Estimations and Imputations for Missing Data
For essential data to pool the outcome of annual rate of change in GFR, we used estimation and imputation methods to reconstruct the missing values as recommended in the Cochrane Handbook. 1 The formula: [standard deviation (SD) = N × standard error (SE)] was used to obtain SD from SE, where N = sample size. The formula: [SD = N × (upper limit of confidence interval -lower limit of confidence interval) / 3.92] was used to obtain SD from confidence intervals. In the study reported by Klahr in 1994, 8 we estimated the annual rate of change in GFR and SD in patients with different levels of proteinuria from the figure. To obtain a mean value of annual GFR decline rate for each study arm in the studies reported by Schrier in 2002, 9 the means of subgroups were combined using the following formula: (N1M1 + N2M2)/(N1+N2), where N = sample size, M = mean of each subgroup, and we used SD of the entire study group under the assumption that SD of each study arm was the same. In the study reported by Ruggenenti in 2005, 10 we substituted the mean value from the median value, imputed the SD from the interquartile range (IQR) using the formula: [IQR = 1.35 × SD], and multiplied the monthly data by 12 to estimate the annual data. We used between-group P value to impute the SD for the study reported by Hayashi in 2010. 11 For the SD of each study arm in the study reported by Schrier in 2014, 12 we imputed it from confidence interval of the between-group mean difference, under the assumption that SD of each study arm was the same.
eFigure 3. Risk of Bias Graph of Included Studies.
Each methodological quality item is presented as percentages across all included studies. The figure was generated using Review Manager Version 5.1. The unit for the annual rate of change in glomerular filtration rate is mL/min/1.73 m 2 /y. The pooled effect size are expressed as mean difference (MD) with 95% confidence interval (CI). The annual rate of decline in glomerular filtration rate was significantly slower for intensive control group if MD was significantly greater than zero, and vice versa. P for interaction between subgroups = .09. SD, standard deviation; and W, weight. Abbreviations. CI, confidence interval; ESRD, end-stage renal disease; GFR, glomerular filtration rate; N, number of studies.
